Utilization of Non-human Viruses as Recombinant Vector Vaccines against Newly Emerging Human Viral Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 214
Special Issue Editors
Interests: influenza vaccine
Interests: vaccine; gene therapy; molecular biology; genetics; herpesviruses; poxviruses; adenoviruses; other DNA and RNA viruses
Special Issue Information
Dear Colleagues,
The emergence of new viral diseases continues to pose ongoing global health challenges, underscoring the need for efficient vaccines.
Herpesviruses, adenoviruses, poxviruses, and baculoviruses are potential vectors for antigens from various pathogens. This Special Issue highlights recent research and advancements regarding the use of non-human viruses as vectors and discusses recent research and advancements on this topic. It discusses their benefits, challenges, and future directions. Research areas may include non-human viruses, recombinant vector vaccines, emerging human viral diseases, vaccine development, immunogenicity, the immune response, comparative vaccine studies, and clinical trials.
Dr. Dayan Wang
Dr. Abdo Said
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- recombinant vector vaccines
- non-human viruses (herpesviruses, adenoviruses, poxviruses, and baculoviruses)
- vaccine development
- immunogenicity
- immune response
- comparative vaccine studies
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
